Literature DB >> 17707556

An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh.

Ann Levin1, Carol Levin, Debra Kristensen, Dipika Matthias.   

Abstract

This paper evaluates the incremental health and programmatic cost impacts of new vaccine products, as compared to the standard vaccine products in multi-dose vials in Cambodia, Ghana, and Bangladesh. The authors use a cost-effectiveness model to estimate the impacts of introducing four thermostable vaccines with single-dose presentations: measles, yellow fever, bacille Calmette-Guérin, and diphtheria-tetanus-pertussis-hepatitis B. The effectiveness of all of the vaccines increases with the thermostable formats. The incremental costs associated with the introduction of thermostable vaccines increases for three out of four vaccines. Single-dose presentations of thermostable vaccines are potentially cost-effective interventions to reduce childhood deaths and disability in low-resource settings in Asia and Africa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707556     DOI: 10.1016/j.vaccine.2007.06.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

2.  Annual World Vaccine Congress 2014: a re-evaluation of the value proposition for increasing vaccine thermostability.

Authors:  Roland Derwand
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Fairer financing of vaccines in a world living with COVID-19.

Authors:  Itamar Megiddo; Justice Nonvignon; Richmond Owusu; Kalipso Chalkidou; Abigail Colson; Mohamed Gad; Petra Klepac; Francis Ruiz; Alec Morton
Journal:  BMJ Glob Health       Date:  2020-07

4.  The impact of making vaccines thermostable in Niger's vaccine supply chain.

Authors:  Bruce Y Lee; Brigid E Cakouros; Tina-Marie Assi; Diana L Connor; Joel Welling; Souleymane Kone; Ali Djibo; Angela R Wateska; Lionel Pierre; Shawn T Brown
Journal:  Vaccine       Date:  2012-07-10       Impact factor: 3.641

5.  Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.

Authors:  Jessica C Joyce; Marcus L Collins; Paul A Rota; Mark R Prausnitz
Journal:  Adv Ther (Weinh)       Date:  2021-07-28

6.  Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions.

Authors:  Guangchuan Wang; Rui-Yuan Cao; Rong Chen; Lijuan Mo; Jian-Feng Han; Xiaoyu Wang; Xurong Xu; Tao Jiang; Yong-Qiang Deng; Ke Lyu; Shun-Ya Zhu; E-De Qin; Ruikang Tang; Cheng-Feng Qin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

Review 7.  An evaluation of emerging vaccines for childhood meningococcal disease.

Authors:  Debajeet Choudhuri; Tanvir Huda; Evropi Theodoratou; Harish Nair; Lina Zgaga; Rachel Falconer; Ivana Luksic; Hope L Johnson; Jian Shayne F Zhang; Shams El Arifeen; Christopher B Nelson; Ray Borrow; Harry Campbell; Igor Rudan
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

Review 8.  An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children.

Authors:  Daisy Higginson; Evropi Theodoratou; Harish Nair; Tanvir Huda; Lina Zgaga; Suresh S Jadhav; Saad B Omer; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

9.  General method to stabilize mesophilic proteins in hyperthermal water.

Authors:  Xiaoqian Xin; Youwei Xu; Hu Shi; Xiaowen Liu
Journal:  iScience       Date:  2021-05-02

10.  Molecular basis for the thermostability of Newcastle disease virus.

Authors:  Guoyuan Wen; Xiao Hu; Kang Zhao; Hongling Wang; Zhenyu Zhang; Tengfei Zhang; Jinlong Yang; Qingping Luo; Rongrong Zhang; Zishu Pan; Huabin Shao; Qingzhong Yu
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.